Zasocitinib not checked
Takeda · TAK-279 · NDI-034858
FollowEvery change as it happens, and a Monday email
Trials
13 active
26 in total · 13 in the EU
What this is
- How it works
- Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.-citinib: Janus kinase inhibitors WHO name stem
- Tested for
- Psoriatic Arthritis (4 trials), Crohn's Disease (3 trials), Plaque Psoriasis (2 trials), Ulcerative Colitis (2 trials), Palmoplantar Psoriasis, Hidradenitis Suppurativa, Nonsegmental Vitiligo
- Main trialPhase 3
- “Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.”In the company’s words, NCT06671483 on ClinicalTrials.gov
- Other names
- TAK-279 · NDI-034858
Other drugs for Psoriatic Arthritis
- SHR0302Hengrui · Phase 3
- SonelokimabMoonLake Immunotherapeutics AG · Phase 3
- IcotrokinraJanssen Research & Development, LLC · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- UstekinumabJanssen Research & Development, LLC · Phase 3
- TildrakizumabSun Pharma · Phase 3
Coming up12
- 5 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 17 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 26 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
- 18 May 2027Phase 3 trial completes · ClinicalTrials.gov
- 18 May 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 May 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Mar 2028Phase 2 trial completes · ClinicalTrials.gov
- 5 Aug 2029Phase 3 trial completes · ClinicalTrials.gov
- 18 Dec 2029Phase 3 trial completes · ClinicalTrials.gov
- 30 Dec 2029Phase 2 trial completes · ClinicalTrials.gov
- 18 Apr 2030Phase 3 trial completes · ClinicalTrials.gov
- 3 Jul 2034Phase 3 trial completes · ClinicalTrials.gov
Changes2
Last 90 days- 16 NovCompletion date moved: 2033-01-24 to 2034-07-03 · ClinicalTrials.gov NCT07250802
- 12 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT06671483
Trials26
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 18 May 2027 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | |
| Phase 3Active, not recruiting | 18 May 2027 | A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | |
| Phase 3Not yet recruiting | 30 May 2027 | A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis | |
| Phase 3Active, not recruiting | 5 Aug 2029 | A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis | |
| Phase 3Recruiting | 18 Dec 2029 | Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis | |
| Phase 3Not yet recruiting | 18 Apr 2030 | A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) | |
| Phase 3Recruiting | 3 Jul 2034 | A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis | |
| Phase 2Active, not recruiting | 14 Jul 2026 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 2Active, not recruiting | 5 Feb 2027 | A Study of Zasocitinib in Adults With Hidradenitis Suppurativa | |
| Phase 2Recruiting | 17 Feb 2027 | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 2Active, not recruiting | 26 Mar 2027 | A Study of Zasocitinib in Adults With Nonsegmental Vitiligo | |
| Phase 2Recruiting | 30 Mar 2028 | A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease | |
| Phase 2Recruiting | 30 Dec 2029 | A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) | |
| Phase 3Completed | 6 Dec 2024 | A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period | |
| Phase 3Completed | 22 Jan 2025 | A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment | |
| Phase 3Completed | 17 Oct 2025 | A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | |
| Phase 3Completed | 22 Apr 2026 | A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis | |
| Phase 2Completed | 19 Aug 2022 | Study of NDI-034858 in Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 2Completed | 4 May 2023 | A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis | |
| Phase 1Completed | 18 Dec 2023 | A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults | |
| Phase 1Completed | 15 Apr 2024 | A Study of TAK-279 in Adults With or Without Liver Damage | |
| Phase 1Completed | 3 May 2024 | A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults | |
| Phase 1Completed | 22 May 2024 | A Study of TAK-279 in Adults With or Without Kidney Problems | |
| Phase 1Completed | 25 Jun 2024 | A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements | |
| Phase 1Completed | 23 Jul 2024 | A Study of TAK-279 in Healthy Chinese Adults | |
| Phase 1Completed | 11 Mar 2025 | A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026